HolderBook

LIMINATUS PHARMA INC. (LIMN)

Institutional ownership reported to the SEC as of Q2 2026, across 5 quarters.

13
Reporting holders
$69.1K
Reported value
0.9%
Of shares outstanding
0.0%
Held as options
+0
Holder change

Institutions report 616,622 shares against 67,160,362 outstanding. Shares only - option lines are excluded, which is why this can be compared with the company at all. The count comes from the cover page of the company's own most recent report, so it is dated when that was filed rather than at quarter end.

Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.

Holders

FilerValueShares Their book Held Change
XTX Topco Ltd$24.5K221,8390.00%newNEW
GEODE CAPITAL MANAGEMENT, LLC$15.3K138,4180.00%5q+17.5%+$2.3K
CITADEL ADVISORS LLC$6.2K56,0890.00%3q-91.7%-$68.6K
VANGUARD CAPITAL MANAGEMENT LLC$5.5K50,4400.00%2qHELD
GOLDMAN SACHS GROUP INC$4.4K40,2200.00%newNEW
StoneX Group Inc.$3.9K26,0580.00%newNEW
VANGUARD FIDUCIARY TRUST CO$2.5K22,9840.00%2qHELD
STATE STREET CORP$2.1K19,0000.00%5qHELD
UBS Group AG$1.8K16,7300.00%5q-69.3%-$4.2K
Vanguard Personalized Indexing Management, LLC$1.5K13,1480.00%2q-62.1%-$2.4K
Tower Research Capital LLC (TRC)$7837,0930.00%5q-6.3%
BARCLAYS PLC$4744,2900.00%newNEW
BlackRock, Inc.$353130.00%5q-97.6%-$1.4K

Five percent filings

Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →

FiledFormFiler % of class
2026-07-2213GSamda Biolab Co., Ltd.5.1%
2026-07-1413D/AValetudo Therapeutics LLCwith 1 co-filers14.3%
2026-07-0613G/AEwon Comfortech Co., Ltd.10.9%

Quarter by quarter

Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.

QuarterHoldersValue SharesNewAdded TrimmedOptions
Q2 202613$69.1K616,6224150.0%
Q1 202613$188.8K1,097,9702520.0%
Q4 202512$193.5K317,1934220.0%
Q3 202510$437.4K261,9243300.0%
Q2 202510$2.3M207,58810000.0%